华特达因(000915) - 2019 Q1 - 季度财报

Financial Performance - Revenue for the first quarter was CNY 319,791,327.93, a decrease of 29.95% compared to CNY 456,490,788.31 in the same period last year[6] - Net profit attributable to shareholders was CNY 23,919,638.68, down 67.65% from CNY 73,931,901.38 year-over-year[6] - Basic earnings per share decreased by 68.75% to CNY 0.10 from CNY 0.32 in the same period last year[6] - The company's net profit for Q1 2019 was ¥38,834,098.17, a decrease of 71.1% compared to ¥134,332,870.02 in the same period last year[38] - Operating income for Q1 2019 was ¥36,032,570.06, down 25.8% from ¥48,574,773.90 in Q1 2018[40] - Total comprehensive income for Q1 2019 was ¥38,834,098.17, reflecting a significant decline from ¥134,332,870.02 in Q1 2018[38] - The total profit for Q1 2019 was ¥45,730,939.11, a decrease of 71.1% compared to ¥157,844,172.67 in Q1 2018[38] Cash Flow and Liquidity - Net cash flow from operating activities was CNY -76,705,465.97, a decline of 184.35% compared to CNY 90,939,989.43 in the previous year[6] - Cash received from sales of goods and services decreased by 43.62% to CNY 288,857,464.44 in Q1 2019 from CNY 512,300,725.02 in Q1 2018, primarily due to reduced sales collections from Dain Pharmaceutical[14] - The company reported a net cash outflow from operating activities of ¥76,705,465.97, compared to a net inflow of ¥90,939,989.43 in the same period last year[43] - Cash and cash equivalents at the end of the period were ¥694,929,057.31, down from ¥1,004,465,522.00 at the beginning of the period[45] - The company reported a net increase in cash and cash equivalents of -16,628,923.79 CNY, compared to -9,598,390.06 CNY in the previous year[48] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,814,024,005.06, a decrease of 2.96% from CNY 2,899,711,204.80 at the end of the previous year[6] - Total liabilities decreased to CNY 434,647,061.51 from CNY 558,918,759.42, showing improved financial health[29] - The total assets as of January 1, 2019, were 2,899,711,204.80 CNY, with total liabilities at 558,918,759.42 CNY[55] - The company's total liabilities were CNY 88,383,402.64, while total equity reached CNY 729,190,933.55[59] Shareholder Information - Net assets attributable to shareholders increased by 1.48% to CNY 1,621,584,456.82 from CNY 1,597,914,418.14 at the end of the previous year[6] - The total number of ordinary shareholders at the end of the reporting period was 19,903[10] - The largest shareholder, Shandong Shanda Industrial Group Co., Ltd., held 20.72% of the shares[10] - The equity attributable to shareholders of the parent company increased to CNY 1,621,584,456.82 from CNY 1,597,914,418.14, indicating growth in shareholder value[29] Research and Development - Research and development expenses increased by 136.74% to CNY 12,015,812.44 in Q1 2019, compared to CNY 5,075,533.21 in Q1 2018, indicating a significant increase in R&D investment[14] - Research and development expenses increased to ¥1,664,743.51, up 67% from ¥996,979.67 in the previous year[40] Financial Changes and Strategies - The company reported non-recurring gains and losses totaling CNY 284,453.72 during the reporting period[9] - The company is focusing on market expansion and new product development as part of its strategic initiatives for future growth[36] - The company has implemented new financial instrument standards affecting the classification and measurement of financial assets starting January 1, 2019[54]